ImClone enrolls Erbitux Phase IIIs

IMCL completed enrollment in three Phase III trials of Erbitux cetuximab for colorectal, head and neck and lung cancers. All three are measuring survival as the primary endpoint and are comparing Erbitux plus various chemotherapies versus chemotherapy alone.

The international EPIC study enrolled 1,300 patients with metastatic colorectal cancer who are refractory to first-line chemotherapy. The European EXTREME study enrolled 442 patients with recurrent and/or metastatic head and neck cancer. The international FLEX study enrolled 1,124 chemotherapy-naive patients with stage IIIb/IV lung cancer. ...